Trial site
Yuncheng Central Hospital
Yuncheng, Shanxi 044099, ChinaNot linked to an institution yet
- 18running trials
- 5closed trials
The trials here
What the 23 trials at this site are about, from their registry records.
- Phase
- Phase 319 trials
- Phase 23 trials
- Status
- Recruiting9 trials
- Not yet recruiting6 trials
- Completed5 trials
- Active, not recruiting3 trials
- Lead sponsor
- Boehringer Ingelheim2 trials
- Capital Medical University2 trials
- Shenzhen HighTide Biopharmaceutical Ltd.2 trials
- Amgen1 trial
- Beijing 302 Hospital1 trial
- and 15 more
Running trials
Recruiting
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07687459· Phase 3· InSilico Medicine Hong Kong Limited· Source
Contact: Qinhan Chen
Not yet recruiting
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
NCT07797231· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Lijun Chang, Master of medicine
Recruiting
Qishen Yiqi Dripping Pills in Treatment of Chronic Heart FailUre
NCT07687186· Phase 3· Tasly Pharmaceutical Group Co., Ltd· Source
Contact: Yanling Qu
Recruiting
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Posterior Circulation Large Vessel Occlusion Stroke
NCT07509645· Phase 3· Capital Medical University· Source
Contact: Bin Wang
Recruiting
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
NCT07385703· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source
Contact: Li Jia, Master
Recruiting
Phase II Trial of RC1416 Injection in Asthma
NCT07403487· Phase 2· Nanjing RegeneCore Biotech Co., Ltd.· Source
Contact: Zhang Hai Xia
Active, not recruiting
RBD5044 in Chinese Participants With Hypertriglyceridemia
NCT07587788· Phase 2· Ribotek Biopharmaceuticals (Shandong) Co., Ltd· Source
Active, not recruiting
A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)
NCT07230119· Phase 3· Beijing QL Biopharmaceutical Co.,Ltd· Source
Recruiting
Albumin for Patients With Acute Large Vessel Occlusive Stroke Undergoing Endovascular Therapy -2
NCT07263308· Phase 3· Capital Medical University· Source
Contact: Bin Wang
Recruiting
TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer
NCT07047365· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Xiaoke Hou, Master
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459· Phase 3· Amgen· Source
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
NCT06926647· Beijing 302 Hospital· Source
Contact: Lijun Chang
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574· Phase 3· Cytokinetics· Source
Contact: Cytokinetics MD
Recruiting
ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis
NCT06775860· Phase 3· Beijing InnoCare Pharma Tech Co., Ltd.· Source
Contact: Juanli Fan
Recruiting
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
NCT06424288· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626· Phase 3· LeonaBio· Source
Contact: Xiaoke Hou
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer
NCT05346224· Phase 3· Shanghai Henlius Biotech· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error